- Home
- GDTC vs ANTX Comparison
GDTC vs ANTX Comparison
Compare GDTC & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- ANTX
- Stock Information
- Founded
- GDTC 2018
- ANTX 2017
- Country
- GDTC Singapore
- ANTX United States
- Employees
- GDTC N/A
- ANTX N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- ANTX Health Care
- Exchange
- GDTC Nasdaq
- ANTX Nasdaq
- Market Cap
- GDTC 28.0M
- ANTX 33.2M
- IPO Year
- GDTC 2023
- ANTX 2022
- Fundamental
- Price
- GDTC $1.86
- ANTX $1.13
- Analyst Decision
- GDTC Buy
- ANTX Buy
- Analyst Count
- GDTC 1
- ANTX 2
- Target Price
- GDTC $5.00
- ANTX $2.00
- AVG Volume (30 Days)
- GDTC 10.3K
- ANTX 91.2K
- Earning Date
- GDTC 01-01-0001
- ANTX 08-12-2025
- Dividend Yield
- GDTC N/A
- ANTX N/A
- EPS Growth
- GDTC N/A
- ANTX N/A
- EPS
- GDTC N/A
- ANTX N/A
- Revenue
- GDTC $368,838.00
- ANTX N/A
- Revenue This Year
- GDTC $5.37
- ANTX N/A
- Revenue Next Year
- GDTC N/A
- ANTX N/A
- P/E Ratio
- GDTC N/A
- ANTX N/A
- Revenue Growth
- GDTC N/A
- ANTX N/A
- 52 Week Low
- GDTC $1.20
- ANTX $0.87
- 52 Week High
- GDTC $4.05
- ANTX $2.95
- Technical
- Relative Strength Index (RSI)
- GDTC 41.07
- ANTX 57.39
- Support Level
- GDTC $1.96
- ANTX $1.05
- Resistance Level
- GDTC $2.26
- ANTX $1.15
- Average True Range (ATR)
- GDTC 0.10
- ANTX 0.03
- MACD
- GDTC -0.02
- ANTX 0.01
- Stochastic Oscillator
- GDTC 17.95
- ANTX 85.00
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.